These phenomena usually result in the failure of antitumor effects of infiltrating T cells by extrinsic PD-1/PD-L1 axis thus adding rational to the simultaneous targeting of CSCs and the PD-1/PD-L1 axis in cancer immunotherapies. The gene discussed is PDCD1; the disease is cancer.